NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

I think that for the patient perspective, this is great promise for turning these cancers into manageable diseases as you pile on treatment upon treatment and successfully increase the OS. However from an investor perspective, this could prove unsustainable. So if for example each treatment added to the mix demands something like $250,000 for its part of the treatment, which seems now to be the going rate for many of these treatment, when you pile on say for such treatments in a combo, you now get to an unsustainable increase in the treatment cost per patient. The only way to keep the per patient cost "reasonable" is to cut the individual take for each of the component treatments that are part of the combo. Thus each individual treatment will have to accept say $75,000 to $100,000 to limit the total cost per patient to limit the total cost of the combo rather than the say $250,000 that DCVAX is now expected to get. Any thoughts?